Insiders Are Buying Processa Pharmaceuticals and 2 Other Penny Stocks Insiders Are Buying Processa Pharmaceuticals And 2 Other Penny Stocks

Written By Michael Gary Scott

On Wednesday, the Dow Jones index showed optimism by closing higher around 150 points. Insiders sending bullish signals through stock purchases can infuse some much-needed confidence in the unpredictable landscape of penny stocks.

Below is a closer look at notable insider purchases for three particular penny stocks, offering investors and traders a glimpse into potential future trajectories for these companies. This peek at insider activity may play a substantial role in investment or trading decisions concerning these penny stocks. For a comprehensive examination, it may be beneficial to explore Benzinga’s platform dedicated to insider transactions.


Abeona Therapeutics


  • The Insider Move: Abeona Therapeutics Inc. ABEO Director and Chief Executive Officer Vishwas Seshadri has recently bolstered his confidence by acquiring 20,000 shares at an average price of $4.39. The total cost of this acquisition tallies up to approximately $87,800.
  • Company Developments: Abeona Therapeutics recently provided an update on the progress of the Pz-cel Biologics License Application.
  • About Abeona Therapeutics: A clinical-stage biopharmaceutical company, Abeona Therapeutics Inc is dedicated to developing gene therapies and plasma-based products to combat life-threatening rare genetic diseases.


OPKO Health


  • The Insider Move: OPKO Health, Inc. OPK saw Frost Gamma Investments Trust, a 10% owner, acquire a hefty 1,500,000 shares at an attractive average price of $0.98. This notable purchase demanded a substantial investment of approximately $1,462,800.
  • Company Developments: OPKO Health recently completed a private offering of $200 million in convertible senior notes due 2029.
  • About OPKO Health: A multifaceted biotechnology company, OPKO Health Inc is engaged in diverse pharmaceutical and diagnostic development programs.
See also  Exploring the Potential: Company Makes Strides in Identifying Project Targets Exploring the Potential: Company Makes Strides in Identifying Project Targets


Processa Pharmaceuticals


  • The Insider Move: Processa Pharmaceuticals, Inc. PCSA received a vote of confidence from Director and President of Research & Development, David Young. He acquired 20,000 shares at an average price of $2.53, amounting to a total spending of approximately $50,504.
  • Company Developments: Processa Pharmaceuticals recently regained compliance with the Nasdaq.
  • About Processa Pharmaceuticals: A clinical-stage United States-based biopharmaceutical company, Processa Pharmaceuticals Inc is dedicated to combatting various medical conditions.